CureVac up 13% as court upholds validity of patent in BioNTech spat

Matthias Hangst/Getty Images News CureVac ( NASDAQ: CVAC ) is up ~13% in after-hours trading Thursday after the European Patent Court deemed valid a key patent that the biotech says is central to its technology amid a challenge from German rival BioNTech ( NASDAQ: BNTX ). The patent in question, EP.